Celcuity (CELC) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Celcuity (NASDAQ: CELC) in the last few weeks:

• 5/28/2026 – Celcuity was given a new $160.00 price target by Macquarie Infrastructure Holdings, LLC.
• 5/28/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/19/2026 – Celcuity was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/18/2026 – Celcuity had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a “buy” rating on the stock.
• 5/15/2026 – Celcuity had its price target raised by Wells Fargo & Company from $150.00 to $183.00. They now have an “overweight” rating on the stock.
• 5/15/2026 – Celcuity had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $157.00 price target on the stock.
• 5/4/2026 – Celcuity had its “buy” rating reaffirmed by Craig Hallum. They now have a $189.00 price target on the stock.
• 5/4/2026 – Celcuity had its price target raised by Guggenheim from $135.00 to $165.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Celcuity was given a new $150.00 price target by Stifel Nicolaus.
• 5/4/2026 – Celcuity had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/4/2026 – Celcuity had its price target raised by Citizens Jmp from $150.00 to $160.00. They now have a “market outperform” rating on the stock.
• 5/4/2026 – Celcuity had its price target raised by Needham & Company LLC from $122.00 to $157.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Celcuity is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
• 4/27/2026 – Celcuity is now covered by Citizens Jmp. They set a “market outperform” rating and a $150.00 price target on the stock.
• 4/25/2026 – Celcuity was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/20/2026 – Celcuity had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock worth $5,111,950 over the last three months. Corporate insiders own 13.33% of the company’s stock.

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.